Uveitis - Pipeline Review, H Uveitis - Pipeline Review, H2 2016

Transcription

1 Uveitis - Pipeline Review, H No of Pages 194 Publishing Date - September 30, 2016 Browse detailed TOC, Tables, Figures, Charts in Uveitis - Pipeline Review, H at- Uveitis - Pipeline Review, H Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2016, provides an overview of the Uveitis (Ophthalmology) pipeline landscape. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by

2 Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 8, 2, 1, 26 and 6 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Uveitis. Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

3 Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter- strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know- how what drove them from pipeline. Ask for Discount at Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Uveitis Overview 8 Therapeutics Development 9 Pipeline Products for Uveitis - Overview 9 Pipeline Products for Uveitis - Comparative Analysis 10

4 Uveitis - Therapeutics under Development by Companies 11 Uveitis - Therapeutics under Investigation by Universities/Institutes 15 Uveitis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Uveitis - Products under Development by Companies 19 Uveitis - Products under Investigation by Universities/Institutes 22 Uveitis - Companies Involved in Therapeutics Development 23 2-BBB Medicines BV 23 AbbVie Inc 24 Aciont Inc. 25 Aldeyra Therapeutics Inc 26 Apitope International NV 27 Astellas Pharma Inc. 28 Bionomics Limited 29 Bristol-Myers Squibb Company 30 Can-Fite BioPharma Ltd. 31 Clearside BioMedical, Inc. 32 Endocyte, Inc. 33 Enzo Biochem, Inc. 34 EyeGate Pharmaceuticals, Inc. 35 F. Hoffmann-La Roche Ltd. 36 HanAll Biopharma Co., Ltd. 37 Icon Bioscience, Inc. 38

5 KPI Therapeutics, Inc. 39 Midatech Pharma Plc 40 Mitotech S.A. 41 Neuroptis Biotech 42 Novartis AG 43 Oculis ehf 44 OncoNOx ApS 45 OSE Immunotherapeutics 46 Palatin Technologies, Inc. 47 Panoptes Pharma Ges.m.b.H. 48 Pfizer Inc. 49 Precision Ocular Ltd 50 psivida Corp. 51 Regeneron Pharmaceuticals Inc 52 Santen Pharmaceutical Co., Ltd. 53 SynDevRx, Inc. 54 TopiVert Ltd 55 TxCell SA 56 Uveitis - Therapeutics Assessment 57 Assessment by Monotherapy Products 57 Assessment by Target 58 Assessment by Mechanism of Action 61 Assessment by Route of Administration 64 Assessment by Molecule Type 66 Drug Profiles 68

6 2-B Drug Profile 68 abatacept - Drug Profile 70 adalimumab - Drug Profile 75 ANV Drug Profile 83 ATXUV-1 - Drug Profile 84 ATXUV-2 - Drug Profile 85 B27-PD - Drug Profile 86 BNC Drug Profile 87 celecoxib - Drug Profile 88 Col-Treg - Drug Profile 90 CVX Drug Profile 92 cyclosporine SR - Drug Profile 93 dalazatide - Drug Profile 94 dexamethasone acetate - Drug Profile 99 dexamethasone acetate - Drug Profile 103 dexamethasone acetate - Drug Profile 104 dexamethasone sodium phosphate - Drug Profile 105 Drug for Chronic Uveitis - Drug Profile 107 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 108 EBI Drug Profile 109 EC Drug Profile 110 EYS Drug Profile 111 fluocinolone acetonide SR - Drug Profile 112 FR Drug Profile 120 Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile 123

7 HL Drug Profile 124 HO-10 - Drug Profile 125 INV-17 - Drug Profile 126 IVMED-10 - Drug Profile 127 IVMED-20 - Drug Profile 128 KPI Drug Profile 129 LME Drug Profile 130 lodamin - Drug Profile 131 methotrexate - Drug Profile 132 NOP-3 - Drug Profile 133 NS-2 - Drug Profile 134 OX Drug Profile 138 piclidenoson - Drug Profile 139 PL Drug Profile 147 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 148 PP Drug Profile 150 PPL Drug Profile 151 Recombinant Enzymes for Uveitis - Drug Profile 153 sarilumab - Drug Profile 154 sirolimus - Drug Profile 159 Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile 161 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 162 tesidolumab - Drug Profile 164 TOP Drug Profile 166 triamcinolone acetonide - Drug Profile 167

8 Powered by TCPDF ( Powered by TCPDF ( Uveitis - Dormant Projects 171 Uveitis - Discontinued Products 175 Uveitis - Product Development Milestones 176 Featured News & Press Releases 176 Appendix 189 Methodology 189 Coverage 189 Secondary Research 189 Primary Research 189 Expert Panel Validation 189 Contact Us 189 Disclaimer 190 Report Details Date of Publishing - September 30, 2016 No of Pages 194 Single User PDF License $2000 Corporate License $6000 Buy Now - About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact Mr. Ameya Pingaley Absolute Reports sales@absolutereports.com